Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 4Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Bendamustine Hydrochloride × Thoracic × Clear all
NCT00984542 2014-03-12

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
50 enrolled 11 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡